India’s Stem Cell Guidelines Mandate Additional Checks
Executive Summary
Draft update to national guidelines factors in additional safeguards and makes it mandatory to establish institutional panels to review stem cell research. Gene editing would be an area of "restrictive" research.
You may also be interested in...
India Proposes Classifying Manipulated Cells And Tissue Products As Drugs
The Indian government is proposing to change the definition of a new drug to include substantially manipulated stem cell and tissue-based therapies.
Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
Editas Competitor CRISPR Therapeutics Hails European Patent Decision
CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.